IntraLase Stockholders Approve Merger With Advanced Medical Optics

IRVINE, Calif., March 30  /PRNewswire-FirstCall/ -- IntraLase Corp. (NASDAQ:ILSE) announced today that its stockholders have approved the merger with Advanced Medical Optics, Inc. (NYSE:EYE). A substantial majority of outstanding shares were cast in favor of the merger.  The merger is expected to close shortly.

On January 8, 2007 Advanced Medical Optics and IntraLase announced that they had entered into a definitive agreement for AMO to acquire all outstanding shares of Common Stock and outstanding options to acquire Common Stock of IntraLase for approximately $808 million, or $25.00 per share, in cash, subject to certain deductions and tax witholdings.

IntraLase further announced today that, in connection with the merger, it has submitted written notice to the Nasdaq Global Market of its intention to file a Form 25 with the Securities and Exchange Commission, or SEC, in order to voluntarily delist its shares of Common Stock from Nasdaq and deregister its shares under the Securities Exchange Act of 1934.  IntraLase has requested that the delisting become effective on April 3, 2007.  Following the delisting of IntraLase's shares from Nasdaq, IntraLase will no longer be required to file reports with the SEC, including quarterly, annual and current reports.

About IntraLase Corp.

IntraLase designs, develops, and manufactures an ultra-fast laser that is revolutionizing refractive and corneal surgery by creating safe and more precise corneal incisions. Delivering on the promise of ophthalmic laser technology, the IntraLase FS laser, related software, and disposable devices replace the hand-held microkeratome blade used during LASIK surgery. The unsurpassed accuracy of IntraLase's computer-controlled femtosecond laser has been shown to improve safety profiles and visual outcomes when used during LASIK. Additionally, the IntraLase FS laser creates precision-designed intracorneal incisions that when combined can be used during lamellar and penetrating keratoplasty, and intrastromal ring implantation. IntraLase is presently in the process of commercializing applications of its technology in the treatment of corneal diseases that require corneal transplant surgery. The company's proprietary laser and disposable patient interfaces are presently marketed throughout the United States and 33 other countries. IntraLase is headquartered and manufactures its products in Irvine, California. For additional information, visit the company's web site: http://www.intralase.com/.  For information on Advanced Medical Optics, visit their web site: http://www.advancedmedicaloptics.com/site/.

Forward Looking Statements

Statements contained in this press release that are not historical information are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "believe," "expect," "anticipate," "intend," "plan," "estimate," "project," or words of similar meaning, or future or conditional verbs such as "will," "would," "should," "could," or "may."

These forward-looking statements are made only as of the date of this press release, and the company assumes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events, or otherwise. 

DATASOURCE: IntraLase Corp.



CONTACT:  Krista Mallory, Director, Investor Relations and Corporate

Communications of IntraLase Corp., [phone], ext. 260,





Web site:  http://www.intralase.com/

http://www.advancedmedicaloptics.com/site 

Copyright